Table 2. Predicted NBPF genes in the human genome.
Name | Position | No. of DUF1220 | No. of DUF1220 in Triplet | Promoter | NBPF Type |
---|---|---|---|---|---|
NBPF1 | 16,890,412–16,939,982 | 7 | 0 | EVI5/CM | Primate |
NBPF2p | 21,749,601–21,754,300 | 3 | 0 | None | Pseudogene |
NBPF3 | 21,766,631–21,811,392 | 5 | 0 | EVI5/CM | Primate |
NBPF4 | 108,765,963–108,786,703 | 4 | 0 | CM | Nonprimate |
NBPF5p | 108,918,460–108,953,432 | 2 | 0 | CM | Pseudogene |
NBPF6 | 108,992,904–109,013259 | 4 | 0 | CM | Nonprimate |
NBPF7 | 120,377,389–120,387,779 | 2 | 0 | CM | Nonprimate |
NBPF8 | 144,146,807–144,224,481 | 44 | 42 | Gap | HLS |
NBPF9 | 144,593,696–144,828,810 | 7 | 0 | EVI5/CM | Primate |
NBPF10 | 145,293,371–145,368,682 | 40 | 36 | CM | HLS |
NBPF11 | 146,032,543–146,068,252 | 7 | 0 | EVI5/CM | Primate |
NBPF25 | 146,214,651–146,253,110 | 16 | 11 | Gap | HLS |
NBPF12 | 146,374,056–146,467,744 | 34 | 29 | EVI5/CM | HLS |
NBPF13 | 146,581,444–146,596,147 | 5 | 0 | CM | Primate |
NBPF24 | 147,574,324–147,624,601 | 7 | 0 | EVI5/CM | Primate |
NBPF14 | 148,003,643–148,026,039 | 10 | 7 | Gap | HLS |
NBPF20 | 148,251,113–148,346,929 | 52 | 48 | CM (? gap EVI5) | HLS |
NBPF15 | 148,556,090–148,596,267 | 6 | 0 | EVI5/CM | Primate |
NBPF16 | 148,739,442–148,758,311 | 6 | 0 | CM (? gap EVI5) | Primate |
NBPF23 | 149,089,947–149,154,938 | 6 | 0 | EVI5/CM | Primate |
NBPF18p | 151,991,138–152,015,250 | 0 | 0 | CM | Pseudogene |
NBPF21p | Chr3: 36,657,498–36,678,949 | 1 | 0 | None | Pseudogene |
NBPF22p | Chr5: 85,578,262–85,593,362 | 2 | 0 | CM | Pseudogene |
This table was created using the new comprehensive annotation method described here. Listed are the NBPF name, genomic position, number of encoded DUF1220 domains, number of DUF1220 domains intragenically amplified in the HLS triplet clades, and predicted promoters. Genes containing amplified HLS DUF1220 triplets are in bold.